can also be found in children, although this is rare. Regarding the juvenile granulosa cell tumor, the mean age at diagnosis has been reported as 8 to 9 years and 13 to 17 years in series of girls younger than 16 years 7 and in series that included adults, 8 respectively. Because all granulosa cell tumors are hormonally active, producing estradiol, 80% to 90% of patients less than 8 years of age have signs of isosexual precocious pseudopuberty. Precocious breast development, increased pubic hair, vaginal bleeding, advanced growth, and bone age may be observed on examination. A hormonally active juvenile granulosa cell tumor may cause menstrual irregularities and rarely virilization in older patients. Abdominal swelling, pain, and a palpable mass in the lower abdomen are important presenting symptoms in all patients. In 10% of cases, a juvenile granulosa cell tumor may rupture and as the result acute abdominal pain may be the first presenting symptom. Ascites is present in 10% of patients. 9 Bilateral granulosa cell tumors account for 3% of patients and most commonly are limited to the ovaries at the time O varian granulosa cell tumors are rare malignancies that originate from the sex-cord stromal cells of the ovary and represent 2% to 5% of all ovarian cancers. [1] [2] [3] [4] According to their clinical presentation and histologic characteristics, they are divided into 2 subgroups: juvenile granulosa cell tumors and adult granulosa cell tumors. The tumors most commonly affect adults, but 5% present in the prepubertal period. 5 The juvenile form of tumor is diagnosed in patients less than 30, 20, and 10 years of age in 90%, 80%, and 50% of cases, respectively. 6 However, adult granulosa cell tumor Granulosa cell tumors of the ovary are rare neoplasms that originate from sex-cord stromal cells. The long natural history of granulosa cell tumors and their tendency to recur years after the initial diagnosis are the most prominent of their characteristics. The secretion of estradiol is the reason for signs at presentation such as vaginal bleeding and precocious puberty. Abdominal pain and hemoperitoneum, which occasionally can occur, are attributable to tumor rupture. The most common finding in pelvic examination is a tumor mass, which is subsequently confirmed with imaging techniques. Surgery is the mainstay of initial management for histological diagnosis, appropriate staging, and debulking. A more conservative unilateral salpingo-oophorectomy is indicated in patients with stage I disease and patients of reproductive age. Total abdominal hysterectomy with bilateral salpingo-oophorectomy is the appropriate surgical treatment for postmenopausal women and those with more advanced disease. The stage of disease is the most important prognostic factor associated with the risk of relapse. There are no clear conclusions regarding the role of postoperative chemotherapy or radiotherapy in stage I disease and in those with completely resected tumor. The use of adjuvant chemotherapy or radiotherapy has sometimes been associated with prolonged disease-free survival and possibly overall survival. Chemotherapy is the treatment of choice for patients with advanced, recurrent, or metastatic disease, and BEP (bleomycin, etoposide, and cisplatin) is the preferred regimen. Although the overall rate of response to treatment is high, the impact of treatment on disease-free or overall survival is unknown. Prolonged surveillance is mandatory because tumors tend to recur years after the initial diagnosis.
Keywords: granulosa cell tumor; etiology; prognosis; tumor markers; treatment of diagnosis, stage I according to FIGO classification. Juvenile granulosa cell tumors are usually large, averaging 12 cm in diameter, and are either solid or partly or entirely cystic. In the majority of cases the cystic fluid is serous. Regarding tumor size, there are no differences between premenarchal and postmenarchal patients. According to the stage at diagnosis, the majority of women with adult granulosa cell tumor are also diagnosed as having stage I disease (78-91%). 2, 10 Slow growth with a tendency for late recurrence characterizes the natural history of this tumor. 1, 10 In this review we analyze the clinical features of adult granulosa cell tumors and mention the treatment modalities of patients with newly diagnosed and recurrent disease.
Epidemiology
Although granulosa cell tumors can occur at any age, they present most often in women of reproductive age and they occur as well as in women who are postmenopausal. 1-3,10-15 During a 15-year period in Israel, 172 new cases of this tumor were diagnosed, for an incidence of 0.9 cases per 100 000 women per year. 11 The incidence of tumor in women of European and American background was almost twice that of women of African and Asian origin, 0.98 versus 0.522/100 000/y. The reported incidence of granulosa cell tumor has varied from 0.58 to 1.6/100 000/y 10, 11, 15 and was reported as 0.62/100 000/y in Finland. 11 In United States the calculated incidence for white females is 0.99/100 000/y. 3, 11 The median age at presentation in the more common adult form, which generally presents in perimenopausal or postmenopausal women, is 50 years 2,10,11 with a range of 40 to 70 years. 16 Granulosa cell tumor has been reported to be associated with endometrial hyperplasia attributable to stimulation of the endometrium by estrogen production. Approximately 13% of these patients develop welldifferentiated endometrial adenocarcinoma. 1, 2, 17 In very large unilocular or multilocular thin-walled cystic masses, virilism may be observed. 2, 18 Despite the association with excessive hormone production, patients with granulosa cell tumors have not demonstrated an increased incidence of infertility. 11 Willemsen et al 19 treated 12 granulosa cell tumors with clomiphen, gonadotrophins, or both for ovarian hyperstimulation. These investigators postulated 3 explanations for the possible relation of ovarian stimulation and granulosa cell tumor. First, the granulosa cell tumor is present in the ovary, waiting for a hormonal trigger; second, increased follicle-stimulating hormone concentrations are oncogenic to granulosa cell tumor; and third, the onset of the granulosa cell tumor during ovarian stimulation is coincidental. It has been reported that mutations of BRCA1 or BRCA2 have not been associated with a higher risk of developing granulosa cell tumors. 3
Clinical Presentation
Abnormal uterine bleeding and pain attributable to the large size of granulosa cell tumors are the most common presenting symptoms. In the reproductive age group, patients may have menstrual irregularities, menorrhagia, intermenstrual bleeding, or amenorrhea, and in postmenopausal women, abnormal uterine bleeding may be the presenting symptom. 2, 9, 12, 15, 20 In older patients, the symptoms of granulosa cell tumors may mimic those of common epithelial ovarian cancer, such as vague abdominal discomfort, increasing abdominal girth, and weight loss. Schwartz and Smith 21 treated 51 patients with granulosa cell tumors and noted that the majority of patients were in the fifth and sixth decades of life. The most common presenting symptoms were postmenopausal bleeding, the presence of a mass, and pelvic or abdominal mass. Similar presenting symptoms were reported by Fox et al 2 and Ohel et al. 11 In approximately 10% of patients, the tumor is either discovered at the time of surgery for abnormal bleeding or found only after histologic examination of the specimen. 22 Endometrial hyperplasia is also frequently present attributable to the endogenous estrogen effect. Approximately 25% to 50% of granulosa cell tumors are associated with endometrial hyperplasia, whereas 5% to 13% are associated with an endometrial carcinoma. 1, 2, 12, 15, 23 Occasionally, endometrial carcinoma may be diagnosed incidentally at the time of surgical staging performed for granulosa cell tumors. Endometrial carcinoma related to granulosa cell tumors is usually well differentiated, diagnosed at an early stage, and associated with a good prognosis. 1, 10, 22 Granulosa cell tumors may also be associated with breast enlargement and tenderness attributable to the endogenous estrogen effect.
The juvenile variant of granulosa cell tumor usually occurs before the normal age of puberty and is associated with histologic features that distinguish it from the adult granulosa cell tumor. Isosexual precocity is often present in patients with juvenile granulosa cell tumors. 2, 9, 24 An association has been found with Potter's syndrome, 25 multiple congenital abnormalities, 26 Ollier's disease (multiple enchondromatosis), 27, 28 and Maffucci's syndrome (Ollier's disease with hemangioma). 29 Approximately 90% of granulosa cell tumors found in prepubertal patients, and many tumors found in women younger than 30, are juvenile granulosa cell tumors. 6 Rare cases have also been reported of androgen-secreting granulosa cell tumors causing the development of virilizing features or hirsutism. 30, 31 Persistent, localized abdominal or pelvic pain, sometimes associated with abdominal distension from a large ovarian mass, may be described by patient. Occasionally, ovarian torsion can cause more acute onset of pelvic pain. Although torsion can produce acute abdominal signs and symptoms, a huge hemorrhagic granulosa cell tumor may be relatively asymptomatic. 32 Rupture of adult granulosa cell tumors was reported by Stenwig et al 15 to occur in 10% of patients. In the series reported by Schwartz and Smith, 21 35% of the tumors ruptured (13/37). Five of these ruptured within 24 hours of surgery and 8 ruptured at the time of surgery. Premenopausal women who present with ruptured granulosa cell tumors experience acute onset of abdominal pain, abdominal distension, and hypotension caused by the development of hemoperitoneum.
Spread of granulosa cell tumors is local, by direct extension and intraperitoneal seeding. The tumors may also spread hematogenously, and patients can develop metastases in the lungs, liver, and brain years after initial diagnosis. Diddle 33 found that 8% of 110 cases had lymph node metastasis at postmortem examination.
Granulosa cell tumors are the most classic late-recurring malignancies in gynecology. 2 After the initial diagnosis, recurrences may not be detected for more than 5 years. Thirty-seven years was the longest reported time period before recurrence. 34 However, 14 of 19 patients with recurrent granulosa cell tumors were identified within 3 years in the series reported by Schwartz and Smith, 21 and more than half of the recurrences were identified within 2 years in the series reported by Fox et al. 2 Most patients have a palpable abdominal or pelvic mass. 2, 11 Between 80% and 90% of granulosa cell tumors are confined to the ovary. Advanced metastatic disease with ascites is present in about 10% of cases.
Radiographic Findings
Imaging findings in adult granulosa cell tumors vary widely and include solid masses, tumors with varying degrees of hemorrhagic or fibrotic changes, multilocular cystic lesions, and completely cystic tumors. Using echographic and computed tomography (CT) scan findings, Ko et al 35 categorized 13 adult granulosa cell tumors into 5 morphologic patterns: multilocular cystic, thick-walled unilocular cystic, thin-walled unilocular cystic, homogenously solid, and heterogeneously solid. Kim and Kim 36 simplified the categories into 2 most common forms: multiseptated cystic masses and unlobulated solid masses with internal cystic portions. Intratumoral bleeding, infarcts, fibrous degeneration, and irregularly arranged tumor cells have yielded heterogeneously solid tumors. 35, 37 Evidence of hemorrhage has been reported in 60% to 71.4% of cases. 36, 37 On CT scan, hemorrhage is difficult to identify because of an absence of precontrast images. In contrast with epithelial neoplasms, granulosa cell tumors do not have intracystic papillary projections, have less propensity for peritoneal seeding, and are confined to the ovary at the time of diagnosis. Estrogenic effects on the uterus may manifest as uterine enlargement or as endometrial thickening or hemorrhage. 38 
Tumor Markers Estradiol
One of the substances secreted by granulosa cell tumors that is responsible for the clinical signs of hyperestrogenism is estradiol. This secretion may serve as a possible tumor marker for granulosa cell tumors. 39 In patients with known granulosa cell tumors, elevated estradiol levels have been found. However, estradiol levels are not a reliable marker of disease activity, because fluctuating (instead of very high) levels of estradiol have been found in patients with bulky disease, and patients have varied in their response to treatment. 40, 41 Rey et al 41 found no correlation between estradiol levels and course of the disease. Because of the lack of theca cells in the tumor stroma, approximately 30% of cases of granulosa cell tumors do not produce estradiol. Granulosa cell tumors produce estradiol in the presence of theca cells (which are present in some ovarian but not in extraovarian tumors); this action is responsible for the production of androstenedione (estradiol precursor), which is converted to estradiol through the aromatase action present in granulosa cells. 40 Thus, although estradiol may be helpful in monitoring the course of disease, it is not sensitive enough to serve as a reliable tumor marker in this disease.
Inhibin
Inhibin is a dimeric ovarian glycoprotein hormone consisting of an α-subunit and 1 of 2 β-subunits (β A giving inhibin-A or β B giving inhibin-B). 42 Inhibin is a member of the transforming growth factor-β family of growth factors. Suppression of the synthesis and secretion of the pituitary follicle-stimulating hormone (FSH) is the major biological property of inhibin and serves as a component of the pituitary gonadal feedback system. The role of Inhibin in that system has been established, particularly in the female. 43 A related member of the inhibin superfamily is activin, which consists of 3 possible forms (
Unlike inhibin, activin stimulates the secretion of FSH and has actions in a variety of other tissues. The granulosa cell tumor has shown positive staining for inhibin-A and the activins. 44 Inhibin species may be secreted by granulosa cell tumors and serve as useful tumor markers, although inhibin-B may be more frequently elevated in patients with granulosa cell tumors. [45] [46] [47] It is generally accepted that patients with granulosa cell tumor have elevated serum concentrations of these substances, which fall following tumor removal and could serve as a marker of tumor recurrence. 40 More recently, it was reported that 82% of postmenopausal women with mucinous carcinoma of the ovary had elevated serum immunoreactive inhibin concentrations. 48 These levels became undetectable 1
week following tumor removal. The observation that serum inhibin levels fall following tumor removal was consistent with the possibility that elevated inhibin concentrations were the result of secretion of the hormone, either by the tumor tissue or by neighboring normal ovarian tissue. Lappohn et al 40 reported elevated inhibin levels and low FSH levels in 2 patients with residual or recurrent disease. The investigators concluded that inhibin was a more reliable tumor marker of disease activity than estradiol. These results were confirmed by other investigators. 48, 49 
Follicle Regulatory Protein (FRP)
FRP is secreted by granulosa cells and is normally present in the serum of a regularly menstruating woman. The regulation of FRP secretion occurs with differentiation of granulosa cells. Elevated levels of FRP have been detected in some patients with granulosa cell tumors. 50 The clinical importance of this marker is not yet known.
Mullerian Inhibitory Substance (MIS)
Mullerian inhibitory substance is a new potential tumor marker for granulosa cell tumors. In females, MIS is produced by the granulose cells in the developing follicles of the ovary. MIS as a marker for granulosa cell tumors was evaluated by Rey et al. 41 Serum anti-Mullerian hormone concentrations were determined in 16 patients with an adult-type granulosa cell tumor; in 75 female patients with ovarian adenocarcinoma, benign ovarian cysts, or extraovarian cancers; and in 58 normal premenopausal and postmenopausal women. Serum MIS, α-inhibin, and estradiol levels were compared in 10 patients with granulosa cell tumor during 6 to 47 months of follow-up. Serum MIS was undetectable in normal postmenopausal women and was less than 5 μg/L in premenopausal women. Normal serum levels were found in patients with ovarian cancers or cysts or with extraovarian cancers. Levels were between 6.8 and 117.9 μg/L in 8 of 9 patients with a progressive granulosa cell tumor. In the remaining patient, MIS, α-inhibin, and estradiol concentrations were normal. Serum MIS and α-inhibin levels became elevated at least 11 months before the recurrence was clinically detectable. During clinical remission, serum MIS, β-inhibin, and estradiol were normal in most cases. Although the clinical usefulness of MIS is still under investigation, these studies indicate that this hormone may be a useful marker of granulosa cell tumor activity.
Pathology
The gross appearance of granulosa cell tumors varies greatly. Depending on the relative amounts of neoplastic cells and fibrothecomatous stroma, granulosa cell tumors are solid tumors that could be soft or firm and are yellow or gray, depending on amount of intracellular lipid in the lesion. The majority of granulosa cell tumors are predominantly cystic and on external examination may resemble mucinous cystadenoma or cystadenocarcinoma. However, when sectioned, this cyst is generally found to be filled with serous fluid or clotted blood. About 15% of patients with cystic granulosa cell tumors are first examined for acute abdomen associated with hemoperitoneum. Granulosa cell tumors can be well or moderately differentiated. The former pattern may have various presentations, including microfollicular, trabecular, solid tubular, diffuse, and water-silk. However, a mixture of these patterns is often found in an individual tumor. 1, 10, 15, 50 Tumors in the moderately differentiated category have a diffuse pattern that has been designated "sarcomatoid." Occasionally, granulosa cell tumors with a diffuse pattern can be mistaken for a poorly differentiated carcinoma on intraoperative frozen section. Nuclear appearance can be very helpful in distinguishing between granulosa and carcinoma tumors. Undifferentiated carcinomas, adenocarcinomas, and carcinoids may superficially resemble granulosa cell tumors, which can lead to misdiagnosis. The prognosis of these tumors is strikingly different. The appearance of the nuclei is a characteristic feature. Oval or angular, uniform, pale, grooved nuclei are typical of granulosa cell tumors (coffeebean appearance). The nuclei of undifferentiated carcinomas are frequently hyperchromatic, ungrooved, and unequal in size and shape. Nuclear atypia and multiple mitotic figures are also less common in granulosa cell tumors but more frequently observed in undifferentiated carcinomas. Call-Exner bodies are also of diagnostic importance but unfortunately are not often sharply defined.
Prognostic Factors
For granulosa cell tumors, several factors of prognostic significance have been reported. However, studies aimed at defining prognostic factors have been frustrated not only by the relative rarity of these tumors but also by the very long period for which follow-up observation is required. The clinical course of granulosa cell tumors is characterized by indolent growth leading to large tumor size at the time of diagnosis, although in most patients the tumor is still confined to the ovary. The stage is unequivocally the only clinical factor related to recurrence. 2, [10] [11] [12] 14, 50 For patients with granulosa cell tumors, the overall 10year survival rates have been reported as being between 60% and 90%, but the 25-year survival rate is only in the range of 40% to 60%. 2, 9, 15, [50] [51] [52] The 5-year survival rate for patients with stage I ranges from 90% to 95% (>90% survival rate in the majority of the studies). [1] [2] [3] 12, 13, 15, 50 The 10year survival rate is between 85% and 95%. 10, 13, 53 Because 60% to 90% of patients present with stage I disease, 1, 2, 10, 13 the definition of pathologic prognostic factors relates principally to stage I tumors. The 5-year survival rates for stage II and stage III/IV have been reported as 55% to 75% and 22% to 50%, respectively, and the 10-year survival rates for stage I, stage II, and stage III/IV as 84% to 95%, 50% to 65%, and 17% to 33%, respectively 10, 13, 16, 21, 54 (Table  1 ). Regarding the prognostic significance of age, there are conflicting data. 1, 10, 11, 16, 33 Some studies showed an improved prognosis in granulosa cell tumor patients less than 40 years old, 55 whereas others reported a more favorable outcome in patients older than 40 years. 16 Granulosa cell tumors usually have an indolently malignant course, and recurrences following initial therapy commonly occur after more than 5 years, not infrequently after more than 10 years, sometimes after 20 years, and very occasionally after more than 25 years. 56 Thus, even after a disease-free period of 20 years we could not state that the patient is cured without any chance of recurrence. Nevertheless, most recurrences occur within 5 to 10 years following initial therapy, and the reason for defining pathologic prognostic factors is to identify patients with a very long-term risk of recurrence. 2, 10, 11, 14, 52 It has been mentioned that the size of the tumor is of prognostic significance. Independent of stage, patients with tumors measuring 5 cm or less have a better progression-free survival rate and 10-year survival rate than those with tumors greater than 5 cm and those whose tumors measured in excess of 10 cm. 1, 2, 15 Nevertheless, according to other investigators the tumor size was not an important prognostic factor for outcome. 10, 12, 14 In another study, tumors that recurred early were larger than those that recurred after 10 years, and these, in turn, were larger than those that did not recur. In contrast, other investigators showed no significant difference in mean tumor size between those cases that recurred and those without evidence of recurrence. 57 Even microscopic tumors may recur after some years. 58 Tumor rupture in granulosa cell tumor is a factor of prognostic significance. One study showed that patients with intact stage I disease had a 25-year survival rate of 86% whereas those with ruptured tumors of the same stage had a survival rate of 60%. 10 Schneider et al 59 reported no relapses among 12 patients who had accidental stage interstitial cystitis (1C) disease attributable to intraoperative rupture of the tumor capsule. Among these were 3 bilateral tumors treated with adjuvant chemotherapy. In contrast, 5 of 9 patients with stage IC disease who experienced preoperative tumor rupture or malignant ascites relapsed (P = .001). These patients were treated with adjuvant chemotherapy, and 3 developed a recurrence. 59 It has been mentioned that patients whose tumors had a follicular pattern showed a 10-year survival rate of 82%, whereas those with tumors of diffuse pattern had a 29% survival rate. 52 It has also been reported that both insular and diffuse histologic patterns are associated with a poor prognosis. 60 In contrary, other investigators have not recognized the histologic pattern as a prognostic factor in granulosa cell tumors. 50, 51 An association between the mitotic activity index (MI) of granulosa cell tumor and survival or recurrence has been reported in several studies. 10, 12, 14, 15, 55, 58, 61 In one of these studies, patients whose tumors had a low MI (<3 MI per 10 high-power fields [HPFs]) had a 10-year survival of 70% compared with 37% for those whose tumors had higher MI. 15 In a series, 53 tumors that had <4 mitoses/10 HPFs had a more than 2 times risk of recurrence than did those with <3 mitoses/10 HPFs. Furthermore, the disease-free survival rate at 80 months for patients with tumors containing <4 mitoses/10 HPFs was 60% compared with 25% for patients whose tumors showed <4 mitoses/10 HPFs (P < .0005). In another study, MI tended to correlate with stage and was not a prognostic factor in stage I tumors. 2 Studies in which MI either was not a prognostic factor 9 or correlated with the disease stage but was not clearly a predictor for recurrence have reported similar results. Malmstrom et al 12 determined the MI in 42 of 54 cases with granulosa cell tumors and demonstrated in patients with stage I that survival was significantly superior in patients whose tumors had <10 mitoses/10 HPFs.
Nuclear atypia has been reported to be one of the most significant prognostic factors in stage I disease. 15, 54 In one study, the 25-year survival rate for patients whose tumors demonstrated slight atypia was 80%, whereas those whose tumors showed more marked atypia had a 25-year survival rate of 60%. 10 Stenwig et al 15 reported similar results. Nuclear atypia has been reported to be the most important pathologic factor predicting tumor recurrence. 14, 57 Researchers have found significant differences in outcome between tumors that recurred early (nuclear atypia in 77%) and those that recurred late (nuclear atypia in 33%). In contrast, other investigators were unable to show that nuclear atypia was of any prognostic significance. 48, 61 DNA analyses have indicated that 5% to 20% of granulosa cell tumors are aneuploid. According to some investigators aneuploidy was not a predictor for recurrence, 58, [62] [63] [64] whereas others found that aneuploidy was associated with high risk for recurrence. [65] [66] [67] [68] Similar conflicting results have been reported for p53 overexpression; some investigators demonstrated that this was an adverse prognostic factor, 62, 69, 70 whereas others showed no association with I  90-100  84-95  II  55-75  50-65  III/IV  22-50  17-33 outcome. 54, 57, 61, 71 Staining of granulosa cell tumors for Ki-67 showed that a high Ki-67 index was correlated with an adverse prognosis in some studies [60] [61] [62] but not in others. 71, 72 Treatment
Surgical Management
The surgical procedure for patients with granulosa cell tumors has traditionally been similar to that used for epithelial ovarian cancer. Management of recurrence should involve aggressive debulking surgery followed by combination chemotherapy. Although liver, lung, and skeletal metastases can occur, most recurrences are present in the peritoneal cavity. 73 Given the long natural history of granulosa cell tumors, repeated surgical debulking, depending on age, performance status, and resectability of the disease, is a useful method of both controlling symptoms and prolonging survival. The extent of the initial surgery appeared to affect recurrence rates, according to Evans et al. 1 The reported recurrence rate was 17% for patients who underwent TAH BSO compared with 24% for those who had less extensive procedure. However, details relating the surgical procedure to the stage of disease were lacking, so no conclusions can be drawn concerning the relative values of a USO and other forms of surgery. Ohel et al 11 reported a 5year survival rate of 75% in patients who underwent a TAH BSO and 59% in those women who had only USO. Again, from this study, no conclusions can be made about the relative value of conservative versus more extensive surgery. In another study, the recurrence rates were 57% in patients treated with USO and 26% in those undergoing TAH BSO. 16 However, a review of the data showed that 10 of 19 patients who underwent a USO and 4 of 9 who had a BSO had by definition either stage II or III and therefore were at obviously higher risk for recurrence with conservative surgery. In the study by Schneider et al, 59 33 patients underwent adnectomy (salpingo-oophorectomy), which was complete in 18 and incomplete in 15 patients. Sixteen patients had stage IA tumors, 13 patients had stage IC tumors, and 1 patient had a stage III tumor. Four patients experienced disease recurrence after incomplete resection, whereas all completely resected patients remained diseasefree.
Because the majority of patients present with earlystage disease, usually confined to the ovary, a USO should be performed, particularly if the patient wishes to preserve her fertility. In those patients whose fertility is not an issue or those with more advanced disease, it would seem reasonable to complete a TAH BSO with removal of all visible disease.
Radiation Therapy
Radiation therapy has been used to treat granulosa cell tumors either in the adjuvant setting or for recurrent disease. 13, 16, [74] [75] [76] [77] Because of the lack of controlled randomized trials, the role of radiation therapy is not appropriately defined. When given postoperatively, radiation therapy is associated with improved survival. 16, 74, 75 Pankratz et al 16 treated 48 of 61 cases of granulosa cell tumors with adjuvant radiation therapy. The dose to the upper abdomen region ranged from 2000 to 3000 cGy, whereas in the pelvic region the dose was between 3000 and 5000 cGy. The investigators concluded that the group of patients receiving radiation therapy had an improved survival rate compared with those who did not receive radiotherapy. Of 62 patients with granulosa cell tumor treated by Savage et al, 13 8 had received radiation therapy for advanced inoperable disease. As a result of radiation therapy, 3 patients remained disease-free for at least 4 years whereas the overall response rate was 50%. Fourteen received treatment for clinically measurable disease; 20 received adjuvant radiotherapy after surgery for minimal residual (<1 cm) or microscopic residual disease. The moving-strip, whole-abdomen radiation technique with a dose of 28 cGy and a pelvic boost of 28 cGy was used in 10 of 14 patients. The 4 remaining patients were treated with pelvic radiation therapy with 45 to 61 cGy. Six of 14 patients (43%) had a clinical complete response to radiotherapy, with a median follow-up of 13 years (range, 5-21 years). Three of 6 who responded to radiation had relapse 4 to 5 years later; 2 of these 3 died of disease, and 1 was alive with disease at last follow-up. Three responders remain alive without evidence of disease 10 to 21 years after treatment. The 8 nonresponders had a median survival of 12.3 months (range, 1-60 months).
Although radiation therapy is associated with improved survival in newly diagnosed, high-risk patients or patients with recurrent disease, 21, 33, 75, 77 other studies suggest no survival benefit from radiotherapy. 1, [10] [11] [12] Its role in the palliative setting may be for symptomatic disease that can be encompassed by tolerable radiotherapy and in those patients who are suitable for surgical debulking or treatment modalities. Evans et al 1 treated 118 patients with granulosa cell tumors of whom 42 received preoperative or postoperative external beam radiotherapy or radioactive isotope (gold). Radiotherapy appeared to have no effect on recurrence rate: 20% of patients receiving radiotherapy developed recurrence, whereas only 13% of those treated with surgery alone recurred.
There are not sufficient data to support the use of radiation therapy in the adjuvant setting. Moreover, when radiation therapy is indicated as an adjuvant treatment, it is unclear whether whole abdominal irradiation is superior to pelvic irradiation alone.
Chemotherapy
Granulosa cell tumor is potentially responsive to singleagent and combination chemotherapy. In patients with stage I disease the prognosis is excellent, with the longterm disease-free survival rate said to be about 90%, and no further treatment is required after surgery. 1, 10, 13, 15 However, some stage I patients who have large tumors, tumors with high MI, or ruptured tumors may have a higher risk of relapse and may require postoperative chemotherapy. Because of the small number of patients in any reported series, postoperative adjuvant therapy remains controversial. When postoperative therapy is an option, platinum-based chemotherapy is often considered. Although it may be reasonable to consider adjuvant radiotherapy for patients with low-volume residual tumor, the data from the literature do not permit firm conclusions regarding whether radiation therapy is superior to chemotherapy in the adjuvant setting. In patients with stage IV disease and in those with gross residual tumor, platinum-based chemotherapy is the treatment of choice. According to Bjorkholm and Silfversward, 10 patients with clinical stage I disease and ruptured tumor should be treated with 3 courses of BEP (bleomycin, etoposide, and cisplatin). Chemotherapy and hormonal therapy have often been often considered for patients who have advanced/inoperable (stages II, III, IV) or recurrent disease where further surgery or radiotherapy cannot be given for medical or technical reason. Before the introduction of platinum-based chemotherapy, alkylating agents and doxorubicin were reported to have modest activity in granulosa cell tumors, but the responses were short-lived. 21, 74, 75, [78] [79] [80] The next reports appeared on the use of combination chemotherapy consisting of doxorubicin and bleomycin 79 and dactinomycin, cyclophosphamide, and 5-fluorouracil. 21 The introduction of cisplatin has led to different combinations such as cisplatin and doxorubicin, 81 CAP (cyclophosphamide, doxorubicin, and cisplatin), 13, 39, [81] [82] [83] [84] [85] PVB (cisplatin, vinblastine, and bleomycin), 13, [86] [87] [88] and BEP 86, 87 (Table 2 ). Ten patients with advanced or recurrent granulosa cell tumors were treated with CAP. 85 Five complete responses (CR) (3 pathologically documented) and 1 partial response (PR) were obtained for a total response rate of 60%. One pathologically complete responder relapsed after 48 months from the onset of chemotherapy but responded completely to debulking surgery and radiotherapy and remains well with no evidence of disease after more than 87 months. Similarly, Gershenson et al 83 treated 8 patients with metastatic ovarian stromal tumors. Three patients (38%) had a CR to therapy (2 confirmed by second-look laparotomy), and 2 patients (25%) achieved a PR (1 verified by second-look laparotomy). The overall response rate (RR) was 63%.
Although some dose-limiting neurotoxicity and fatalities have been reported, data have shown that PVB is active with previously untreated granulosa cell tumors. [83] [84] [85] Colombo et al 86 treated 11 patients with recurrent and/or metastatic granulosa cell tumors. Six patients achieved a CR and 3 patients achieved a PR, for an overall RR of 74%. Of the complete responders, 5 of 6 remained disease-free at a median follow-up of 17.8 months. Zambetti et al 87 treated 7 patients with advanced/recurrent granulosa cell tumors with PVB. Three CRs (1 pathologically documented) and 1 PR were observed, for an overall RR of 66%. Two complete responders were alive without evidence of disease 7 and 26 months from the start of treatment; the remaining patient relapsed at 15 months. In another series, 13 patients with advanced or recurrent granulosa cell tumors were treated with PVB. 88 The reported CR was 54%, PR 39%, and overall RR 93%. These series established PVB as an active regimen in the treatment of advanced and/or recurrent granulosa cell tumors. Toxicity, however, was significant and included neutropenic sepsis and bleomycin-induced pneumonitis. 86, 87 The BEP regimen in which vinblastine is substituted with etoposide is better tolerated. Although BEP is significantly myelotoxic and is associated with a risk of secondary acute myelogenous leukemia attributable to the inclusion of etoposide, it is associated with decreased peripheral neuropathy. For patients with advanced or recurrent disease, the BEP regimen is recommended for adjuvant postoperative chemotherapy. In case of recurrence, the optimal treatment should involve aggressive debulking surgery followed by combination chemotherapy. Gershenson et al 89 treated 9 patients with metastatic ovarian sex cord-stromal tumors of all types with bleomycin 10 to 15 mg/d by continuous intravenous (IV) infusion on days 1 to 3, etoposide 100 mg/m 2 IV per day on days 1 to 3, and cisplatin 100 mg/m 2 IV on day 1. Of the 6 patients with measurable disease, 2 (33%) had a CR (1 surgical and 1 clinical) and 3 (50%) had a PR, for an overall RR of 83%. Toxicity was acceptable; 2 patients had mild bleomycin pulmonary toxicity. Of the 7 patients with metastatic disease, only 1 (14%) had a durable remission. Median progression-free survival was 14 months. Median survival time was 28 months. The BEP regimen as first-line therapy for ovarian stromal malignancies was evaluated in a phase II trial by the Gynecologic Oncology Group. 90 Negative findings were observed in 37% (14/38) of the patients who underwent second-look laparotomy. The 6 complete responses were of long median duration (24.4 months). Patients with measurable disease were at the highest risk of progression and death. Grade 4 myelotoxicity occurred in 61% of the patients. The investigators reported that 69% of patients with advanced disease and 51% of those with recurrent disease remained progressionfree, with a relatively short median follow-up of 3 years.
Although the efficacy of platinum-based chemotherapy is well established, the role of newer agents such as gemsitabine and oxaliplatin is not known. Single-agent paclitaxel was used in a case report of recurrent granulosa cell tumor with dramatic response. 91 Brown et al 92 showed the potential activity of paclitaxel: of 222 patients identified, 21 were treated with BEP (10 newly diagnosed patients, 11 patients with recurrent disease) and 44 with taxanes (11 newly diagnosed patients, 37 patients with recurrent disease). For newly diagnosed patients treated with BEP compared with those treated with taxanes, the investigators found no significant differences in response rate (82% for both regimens), median progression-free survival (46.1 months for BEP, >52 months for taxanes), and median overall survival (97.2 months for BEP, >52 months for taxane). For recurrent measurable disease, the response rate (71% vs 37%) and the median progression-free survival (11.2 months vs 7.2 months) were also not statistically significant. It is possible that the combination of carboplatin plus paclitaxel, which has been established in the treatment of epithelial ovarian cancer, could have a role in the management of granulosa cell tumors.
In case of recurrence, aggressive treatment should include surgery followed by either radiation therapy or chemotherapy. With these treatment modalities, the disease-free survival is prolonged. [83] [84] [85] [86] [87] For patients previously treated with BEP, the VAC (vincristine, dactinomycin, and cyclophosphamide) regimen is offered. In the treatment of recurrent granulosa cell tumor, if the patient is found to have an isolated metastasis that can be completely resected, then radiation therapy may play a role. One could use a small field of intense radiation therapy, which is associated with prolonged survival. 93 Another treatment option is chemotherapy with BEP for patients with more widespread disease or disease that is suboptimally cytoreduced at the time of relapse.
The treatment of recurrent disease with hormonal therapy is an option, but experience is limited. Schwartz et al 94, 95 reported the presence of estrogen and progesterone receptors in granulosa cell tumors. Those investigators treated their patient, who presented with advanced recurrent disease and progesterone receptor-positive tumor, with oral progestin, and her disease was stabilized for 10 months. Her disease was again stabilized on tamoxifen. 94 Malik and Slevin 96 reported 2 patients treated with high doses of medroxyprogesterone acetate who responded with prolonged remissions after documented widespread recurrence. Similarly, Briasoulis et al 97 reported a PR with megestrol acetate in an elderly woman with granulosa cell tumor and lung metastases lasting for 20 months who had a recurrence after carboplatin chemotherapy. Treatment with a gonadotropin-releasing hormone (GnRH-goserelin) analog achieved a transient PR in 1 patient who had a recurrence after cytotoxic platinum-based chemotherapy. 98 Similarly, Fishman et al 99 treated 6 patients with refractory or progressive granulosa cell tumors after cytotoxic chemotherapy with leuprolide acetate. Among the 5 evaluable patients, 2 achieved PR lasting 3 and 11 months, with disease progression-free intervals of 4 and 12 months. The other 3 patients, including 2 whose disease had progressed on chemotherapy, had stable disease with disease progression-free intervals of 3+, 3+, and 13+ months. The objective response rate was 40%. Cessation of disease progression was noted in all 5 of the evaluable patients. The sixth patient, whose disease could not be evaluated, was treated with leuprolide acetate and had no clinical evidence of disease for 24 months. The therapy was convenient to administer, and no major side effects were noted. In contrast, others have found no benefit of these agents in the setting of recurrent disease. 13
Conclusions
Granulosa cell tumors are rare neoplasms that are characterized by their long natural history and their tendency to recur years after the initial diagnosis. Estradiol secretion is the reason for symptoms and signs at presentation, which include vaginal bleeding and precocious puberty. Tumor rupture causes abdominal pain and hemoperitoneum. A pelvic mass usually is associated with a granulosa cell tumor, which is subsequently confirmed with imaging techniques. The initial treatment of choice is surgery, which is necessary for histological diagnosis, appropriate staging, and debulking. In patients with stage I disease and those of reproductive age, a more conservative surgery, including unilateral salpingo-oophorectomy, is indicated. In postmenopausal women and those with more advanced disease, a total abdominal hysterectomy with bilateral salpingo-oophorectomy is the appropriate surgical treatment. Because most of the patients with granulosa cell tumors present with stage I disease, prognosis is excellent. In more advanced stages and in those with high-risk stage I disease (large tumor size, high MI, ruptured tumor), prognosis is less favorable. Randomized controlled trials to assess the relative benefits of different treatment modalities are not feasible because of the rarity of these tumors. In patients with stage I disease and those with completely resected tumor, the role of postoperative chemotherapy or radiation therapy has not been defined. Besides this, the use of adjuvant therapy has sometimes been associated with prolonged disease-free survival and possibly overall survival. For patients with advanced, recurrent, or metastatic disease, chemotherapy should be considered and BEP is the preferable regimen. Although overall RR is high, the impact on disease-free or overall survival is unknown. Newer cytotoxic agents, such as paclitaxel, have shown promising activity in patients with advanced or recurrent granulosa cell tumors. Finally, because tumors tend to recur years after the initial diagnosis, prolonged surveillance is essential.
